Conmed (CNMD) Cash & Equivalents (2010 - 2026)

Conmed's Cash & Equivalents history runs 17 years deep, the most recent figure standing at $35.0 million for Q1 2026.

• Quarterly Cash & Equivalents fell 1.28% year-over-year to $35.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $35.0 million (down 1.28% YoY) and the FY2025 annual result came in at $40.8 million, up 66.88% from the prior year.
• Cash & Equivalents was $35.0 million for Q1 2026 at Conmed, down from $40.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $53.2 million in Q2 2022 and bottomed at $24.3 million in Q4 2023.
• A 5-year average of $32.9 million and a median of $33.4 million in 2022 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2023 — Cash & Equivalents sank 47.61% — and 2025, when it soared 66.88%.
• Conmed's Cash & Equivalents stood at $28.9 million in 2022, then decreased by 16.05% to $24.3 million in 2023, then grew by 0.67% to $24.5 million in 2024, then surged by 66.88% to $40.8 million in 2025, then declined by 14.18% to $35.0 million in 2026.
• Business Quant data shows CNMD's Cash & Equivalents at $35.0 million in Q1 2026, $40.8 million in Q4 2025, and $38.9 million in Q3 2025.